贝达药业
(300558)
| 流通市值：236.37亿 | | | 总市值：237.13亿 |
| 流通股本：4.19亿 | | | 总股本：4.21亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,731,412,742.27 | 917,554,506.92 | 2,891,950,112.03 | 2,344,643,009.24 |
| 营业收入 | 1,731,412,742.27 | 917,554,506.92 | 2,891,950,112.03 | 2,344,643,009.24 |
| 二、营业总成本 | 1,494,357,686.84 | 730,520,724.15 | 2,460,400,758.66 | 1,978,236,019.16 |
| 营业成本 | 325,829,280.36 | 171,801,799.66 | 538,519,341.59 | 379,678,886.5 |
| 税金及附加 | 20,088,952.57 | 11,539,267.84 | 21,270,693.65 | 14,981,333.66 |
| 销售费用 | 593,574,184.3 | 280,153,932.19 | 1,093,819,859.43 | 870,560,375.36 |
| 管理费用 | 260,676,979.92 | 132,893,502.91 | 268,858,962.29 | 294,428,944.09 |
| 研发费用 | 254,657,824.51 | 113,293,329.82 | 501,901,633.96 | 384,037,587.9 |
| 财务费用 | 39,530,465.18 | 20,838,891.73 | 36,030,267.74 | 34,548,891.65 |
| 其中:利息费用 | 38,893,556.28 | 21,648,799.45 | 45,490,039.66 | 31,546,113.12 |
| 其中:利息收入 | 3,062,516.11 | 1,603,972.57 | 6,782,043.94 | 5,131,459.03 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -76,016,377.9 | -76,599,780.35 | -26,305,321.32 | 46,809,685.04 |
| 加:投资收益 | -6,504,780.23 | -3,160,629.58 | -14,663,608.75 | -6,506,775.59 |
| 资产处置收益 | 72,940.02 | 65,136.6 | -588,954.91 | 121,274.35 |
| 资产减值损失(新) | - | - | -27,460,186.2 | - |
| 信用减值损失(新) | 2,647,368.81 | 533,384.23 | 6,303,473.83 | 6,830,096.41 |
| 其他收益 | 30,893,563.66 | 15,195,343.44 | 31,036,928.55 | 24,610,543.77 |
| 四、营业利润 | 188,147,769.79 | 123,067,237.11 | 399,871,684.57 | 438,271,814.06 |
| 加:营业外收入 | 1,009,542.57 | 409,148.58 | 1,255,593.56 | 211,665.43 |
| 减:营业外支出 | 1,341,243.13 | 323,717.14 | 6,969,176.49 | 6,659,971.9 |
| 五、利润总额 | 187,816,069.23 | 123,152,668.55 | 394,158,101.64 | 431,823,507.59 |
| 减:所得税费用 | 57,108,668.13 | 27,689,152.07 | 7,178,699.06 | 26,669,663.57 |
| 六、净利润 | 130,707,401.1 | 95,463,516.48 | 386,979,402.58 | 405,153,844.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 130,707,401.1 | 95,463,516.48 | 386,979,402.58 | 405,153,844.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 139,897,221.85 | 100,089,181.47 | 402,569,335.69 | 416,225,901.42 |
| 少数股东损益 | -9,189,820.75 | -4,625,664.99 | -15,589,933.11 | -11,072,057.4 |
| 扣除非经常损益后的净利润 | 190,623,726.76 | 164,430,292.77 | 409,834,141.43 | 361,587,573.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.33 | 0.24 | 0.96 | 0.99 |
| (二)稀释每股收益 | 0.33 | 0.24 | 0.96 | 0.99 |
| 八、其他综合收益 | -148,106,979.63 | -137,880,994.15 | 56,915,948.89 | -32,146,129.61 |
| 归属于母公司股东的其他综合收益 | -148,106,979.63 | -137,880,994.15 | 56,915,948.89 | -32,146,129.61 |
| 九、综合收益总额 | -17,399,578.53 | -42,417,477.67 | 443,895,351.47 | 373,007,714.41 |
| 归属于母公司股东的综合收益总额 | -8,209,757.78 | -37,791,812.68 | 459,485,284.58 | 384,079,771.81 |
| 归属于少数股东的综合收益总额 | -9,189,820.75 | -4,625,664.99 | -15,589,933.11 | -11,072,057.4 |
| 公告日期 | 2025-08-20 | 2025-04-25 | 2025-04-18 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |